Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.

2.50
Hdl Handle:
http://hdl.handle.net/10541/72335
Title:
Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
Authors:
Dodd, R L; Slevin, Nicholas J ( 0000-0002-3367-7013 )
Abstract:
Adenoid cystic carcinoma (ACC) accounts for about 1% of all head and neck malignancies. It has a tendency for a prolonged clinical course, with local recurrences and distant metastases sometimes occurring many years after presentation. Standard treatment for salivary gland ACC is surgery and post-operative radiotherapy. The aim of this review was to examine the reported efficacy of various chemotherapy regimens and molecular therapies on recurrent/metastatic salivary gland ACC. One hundred and fourteen publications were reviewed on chemotherapy as well as possible molecular targets of therapy, including KIT, epidermal growth factor receptor (EGFR), human epidermal growth receptor-2 (HER-2), oestrogen and progesterone receptors, proliferating cell nuclear antigen (PCNA), Ki-67 and the p53, bcl-2 and SOX-4 genes. Reported response rates to combination chemotherapy are low and response duration generally short lived. The response to molecular therapies is low also. More research into novel molecular targets is needed.
Affiliation:
Manchester University Medical School, UK.
Citation:
Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. 2006, 42 (8):759-69 Oral Oncol.
Journal:
Oral Oncology
Issue Date:
Sep-2006
URI:
http://hdl.handle.net/10541/72335
DOI:
10.1016/j.oraloncology.2006.01.001
PubMed ID:
16757203
Type:
Article
Language:
en
ISSN:
1368-8375
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDodd, R L-
dc.contributor.authorSlevin, Nicholas J-
dc.date.accessioned2009-07-02T16:11:28Z-
dc.date.available2009-07-02T16:11:28Z-
dc.date.issued2006-09-
dc.identifier.citationSalivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. 2006, 42 (8):759-69 Oral Oncol.en
dc.identifier.issn1368-8375-
dc.identifier.pmid16757203-
dc.identifier.doi10.1016/j.oraloncology.2006.01.001-
dc.identifier.urihttp://hdl.handle.net/10541/72335-
dc.description.abstractAdenoid cystic carcinoma (ACC) accounts for about 1% of all head and neck malignancies. It has a tendency for a prolonged clinical course, with local recurrences and distant metastases sometimes occurring many years after presentation. Standard treatment for salivary gland ACC is surgery and post-operative radiotherapy. The aim of this review was to examine the reported efficacy of various chemotherapy regimens and molecular therapies on recurrent/metastatic salivary gland ACC. One hundred and fourteen publications were reviewed on chemotherapy as well as possible molecular targets of therapy, including KIT, epidermal growth factor receptor (EGFR), human epidermal growth receptor-2 (HER-2), oestrogen and progesterone receptors, proliferating cell nuclear antigen (PCNA), Ki-67 and the p53, bcl-2 and SOX-4 genes. Reported response rates to combination chemotherapy are low and response duration generally short lived. The response to molecular therapies is low also. More research into novel molecular targets is needed.en
dc.language.isoenen
dc.subjectCancer Proteinsen
dc.subjectSalivary Gland Canceren
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Adenoid Cystic-
dc.subject.meshHumans-
dc.subject.meshNeoplasm Proteins-
dc.subject.meshSalivary Gland Neoplasms-
dc.subject.meshTreatment Outcome-
dc.titleSalivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.en
dc.typeArticleen
dc.contributor.departmentManchester University Medical School, UK.en
dc.identifier.journalOral Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.